RDHL.TA - RedHill Biopharma Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
253.10
+2.00 (+0.80%)
At close: 5:24PM IDT
Stock chart is not supported by your current browser
Previous Close251.10
Open254.80
Bid252.80 x 400800
Ask253.10 x 100
Day's Range253.10 - 264.90
52 Week Range183.00 - 343.00
Volume189,991
Avg. Volume186,105
Market Cap718.012M
Beta (3Y Monthly)0.56
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Thomson Reuters StreetEvents

    Edited Transcript of RDHL.TA earnings conference call or presentation 23-Jul-19 12:30pm GMT

    Q2 2019 Redhill Biopharma Ltd Earnings Call

  • 3 Small-Caps That Look Like Bargains at Current Trading Levels
    TheStreet.com

    3 Small-Caps That Look Like Bargains at Current Trading Levels

    No resolution seems on the horizon on the U.S.-China trade front as both sides have dug in their heels. Since the end of February the S&P 500 has continued to advance despite a pullback in May, while the Russell 2000 has stalled out. Let's look at three small-caps that seem like good bargains at current trading levels, starting with BioDelivery Sciences International Inc. .

  • 3 Biotech Stocks That Could Double Your Money
    Motley Fool

    3 Biotech Stocks That Could Double Your Money

    Here's what you need to know about the upgrades and bullish price targets analysts recently slapped on these drugmakers.

  • Reuters

    Tel Aviv shares slide 5 pct in worst day since 2011

    Israeli stocks slid on Sunday, posting their worst daily performance in more than seven years in a broad selloff that followed declines on Wall Street late last week. The Tel Aviv 125 share index closed ...

  • Reuters

    RedHill Biopharma's antibiotic succeeds in late-stage study

    Israel-based RedHill Biopharma Ltd said on Monday its combination antibiotic met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine. The drug, Talicia, eradicated the Helicobacter pylori infection in 84 percent of patients, compared with 58 percent that received a combination of two commonly used antibiotics. RedHill estimates 2.5 million patients are treated annually for H. pylori bacterial infections in the United States.